-

Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference.

Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, May 12 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Revealtest for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Source: Guardant Health, Inc.

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Julie Johnson
julie.johnson@uncappedcommunications.com

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Julie Johnson
julie.johnson@uncappedcommunications.com

More News From Guardant Health, Inc.

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests...

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 10th TD Cowen 46th Annual Health Care Conference in Boston, MA Fireside chat on Wednesday, March 4th at 9:50 a.m. Eastern Time Leerink Partners Global He...

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com....
Back to Newsroom